Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
We’re now just days away from the ’24 elections, and what a race it’s been. Polls have been all over the place, and both parties can make legitimate claims to holding the advantage as we approach Tuesday’s vote.
Amidst the political drama, the stock market has remained robust, with the S&P 500 surging 20% year-to-date. Historically, the index tends to perform well in election years, but this year has been exceptional, making it the most bullish election-year market in decades. A mix of macroeconomic factors, especially expectations of further Fed rate cuts, has fueled strong investor confidence.
Morgan Stanley’s analysts are embracing this momentum, picking out stocks they believe are primed for gains regardless of the election outcome. They’ve zeroed in on two specific stocks poised for substantial growth in the coming year – including one with a potential upside as high as 670%.
As if that weren’t compelling enough, according to the TipRanks database, both stocks are also rated as Strong Buys by the analyst consensus. Let’s see what’s driving this optimism among market experts.
Tenaya Therapeutics (TNYA)
We’ll start with Tenaya Therapeutics, a research-oriented biopharmaceutical company that is focused on developing and producing new therapeutic drugs for the treatment of heart disease. Tenaya is targeting its approach on the underlying causes of heart disease, including rare genetic disorders. The company’s approach includes gene therapies, cellular regeneration, and precision medicines.
Heart disease is the world’s leading cause of death among adults, making its treatment an important niche. Tenaya currently has two primary drug candidates under investigation, TN-201 and TN-401, for the treatment of MYBPC3-associated hypertrophic cardiomyopathy and PKP2-associated arrhythmogenic right ventricular cardiomyopathy, respectively.
The leading candidate, TN-201, is currently undergoing a Phase 1b human clinical trial. The study is focused on safety and tolerability and will enroll up to 24 adults. Data from the first patient cohort in the study are expected to be released in December, presenting a significant milestone for the stock. Meanwhile, enrollment is ongoing for the second cohort.
The second candidate, TN-401, entered its Phase 1 RIDGE-1 trial earlier this year. This global, open-label, dose-escalation study, which will continue patient dosing through Q4 2024, aims to evaluate the safety, tolerability, and effectiveness of a single intravenous dose of TN-401.
Morgan Stanley analyst Michael Ulz views TNYA as a compelling investment, with TN-201 as the primary value driver. Ulz notes, “Interim Ph1b MyPEAK-1 data for TN-201 in nHCM are expected in [December] and represent a key catalyst for Tenaya’s lead program. We see a favorable risk/reward on initial data, which could provide early de-risking, followed by more robust data in 2025.”
“We view favorable trends on cardiac biomarkers and uninterpretable protein expression data as the most likely scenario,” Ulz added. “We believe investors would view the data as positive and suggestive of benefit… Under this scenario we would expect TNYA shares to trade up +100%.”
To this end, Ulz rates TNYA shares an Overweight (i.e. Buy), while his $15 price target offers a whopping ~670% upside from current levels. (To watch Ulz’s track record, click here)
The consensus view here shows that Morgan Stanley’s bullish take is no outlier. TNYA stock has a unanimous Strong Buy consensus rating, based on 7 recent positive analyst reviews. The stock’s $1.94 trading price and $20.20 average target price together suggest an impressive upside of 941% on the 12-month horizon. (See TNYA stock forecast)
Royalty Pharma (RPRX)
The next Morgan Stanley pick we’ll look at is Royalty Pharma, a company that gives investors an interesting way to put money into the biotech sector. Royalty Pharma operates as a royalty company; that is, it purchases ownership rights in biopharmaceutical products and earns royalties on sales and profits. Royalty Pharma has built up a pipeline of such opportunities, designed to generate and maintain a steady stream of revenues.
This royalty strategy has led the company to put together a solid portfolio of assets. Royalty Pharma boasts rights in more than 35 approved products, and backs that up with rights in another 17 drug candidates still in the development stage. Of this total lineup, 15 products are considered ‘blockbusters,’ generating more than $1 billion in annual sales. And for the long term, the company’s portfolio has an average duration of 13 years. In the five-year period from 2018 to 2023, Royalty Pharma deployed an average annual capital of $2 billion, and in calendar year 2023, Royalty Pharma brought in $3 billion in total portfolio receipts.
In its last reported quarter (2Q24), Royalty Pharma reported portfolio receipts (revenue) of $608 million, marking a 12% year-over-year increase, though this came in $18 million below consensus. The company raised its 2024 portfolio receipts guidance to a range of $2.7 billion to $2.775 billion, up from a previous forecast of $2.6 to $2.7 billion. Additionally, the company posted an EPS of $0.96, reflecting a 13% increase year-over-year, slightly shy of the consensus estimate of $0.99.
Checking in with the Morgan Stanley view, we find analyst Terence Flynn taking an upbeat view of the company and its prospects for the long-term.
“RPRX has one of the highest top line growth rates in our coverage and is trading at a discount. In our view the company’s growth profile and diversified portfolio deserves at least an in-line multiple and hence our Overweight rating. We acknowledge that RPRX must continue to deploy capital towards new deals given patent/royalty expiries in order to sustain HSD growth, but management has a strong historical track record on this front. We see two areas of potential upside to estimates that could meaningfully move the needle – AMGN’s Olpasiran/ NOVN’s Pelacarsen for ACVD and JNJ’s Tremfya for psoriasis/IBD,” Flynn opined.
Flynn’s Overweight (i.e. Buy) rating is backed by a $51 price target, suggesting a potential one-year upside of 88%. (To watch Flynn’s track record, click here)
Morgan Stanley isn’t alone in this positive outlook. Royalty Pharma enjoys unanimous support, with 5 Buy ratings and a Strong Buy consensus. Currently priced at $27.10, the stock’s average price target of $44.40 implies a ~64% upside in the coming months. (See RPRX stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
South Korea’s stock market has muscled its way into the world’s top 7, powered by an AI chip rally that has propelled it past two major markets in a matter of weeks. According to Bloomberg data, the country’s listed companies now have a combined market capitalization of $4.59 trillion, edging past Canada’s $4.5 trillion to
What happened: CoreWeave (CRWV) stock sank 11% on Friday. What’s behind the move: The AI data center operator issued a disappointing forecast for the current quarter. The company expects revenue of $2.45 billion to $2.6 billion, falling short of Wall Street’s $2.7 billion expectations. Projected operating income of $30 million–$90 million was well short of
Tech is dominating the stock market and shrinking inside the labor market. That classic K-shaped divide — usually used to describe the US consumer — showed up again Friday after the April jobs report. But this time, the divergence is inside tech itself: Wall Street is paying the highest premiums in at least two decades
The top dot-com stocks were making history in 1999 and 2000. Today’s Nasdaq winners are crushing even those gains. The top 10 performers in the Nasdaq 100 (NDX) over the past year are up an average of 784%, according to BTIG’s Jonathan Krinsky, topping the 622% average gain for the index’s biggest winners in the
It’s a stellar time to be an investor on Wall Street. With rumors swirling of a peace deal between the U.S. and Iran, the benchmark S&P 500 (SNPINDEX: ^GSPC) and growth-stock-propelled Nasdaq Composite (NASDAQINDEX: ^IXIC) screamed to new all-time highs. The iconic Dow Jones Industrial Average (DJINDICES: ^DJI) needs less than a 1% up day
It’s been an incredible last seven years for Wall Street. Except for 2022, the benchmark S&P 500 (^GSPC +0.84%) has gained at least 16% every year for the last seven. We’ve also witnessed the ageless Dow Jones Industrial Average (^DJI +0.02%) and iconic Nasdaq Composite (^IXIC +1.71%) crest psychologically important levels of 50,000 and 25,000,
Palantir Technologies (PLTR +0.52%) has one of the fastest-growing artificial intelligence (AI) businesses on the planet, and as more clients want a piece of its proprietary data analytics platform, growth has been accelerating. The company just reported outstanding first-quarter performance, trouncing Wall Street’s expectations, but Palantir stock remained roughly flat after the report, and it’s
Prudential (02378) rose over 4% in the final trading session. As of press time, it was up 4.59%, trading at HKD 120.7 with a turnover of HKD 20.5788 million. According to Zhitong Finance, Prudential (02378) surged over 4% in the afternoon trading session. As of the time of writing, it rose by 4.59%, trading at
So far this year, the energy sector has been the stock market’s best-performing sector, and it hasn’t been close. While investors greatly appreciate the recent gains, long-term returns ultimately matter more. If you’re looking for an energy stock you can hold for the next decade, look no further than oil and gas giant Chevron (NYSE:
It’s been a record-breaking year for Wall Street. The S&P 500 (SNPINDEX: ^GSPC), Nasdaq Composite (NASDAQINDEX: ^IXIC), and Dow Jones Industrial Average (DJINDICES: ^DJI) have all hit record closing highs and reached psychologically important levels of 7,200, 25,000, and 50,000, respectively. But whether these gains are sustainable is another story. A historic shift at America’s
When Nvidia (NVDA) reports its latest earnings on May 20, it will likely do so with its stock trading at some of the lowest valuation levels in recent memory. Nvidia stock is trading 10x below its three-year median price-to-earnings ratio of 32x, Goldman Sachs analyst James Schneider pointed out in a new note on Friday.
In recent years, stock market observers have noticed that a small group of mega-sized technology stocks, nicknamed the “Magnificent Seven,” have driven an outsized portion of the return in the broad stock market. A decade ago, it was FANGs (Facebook, Amazon, Netflix and Google — sometimes, Apple too) leading the charge. These cadres tend to
SanDisk (SNDK) has become one of the most talked about AI storage plays in 2026. Memory stocks are booming as artificial intelligence drives massive data creation. Data centers need more storage, and that demand is pushing NAND pricing higher. Over the past few months, investors have piled into this space. Stocks have run hard. But
📌 Top story — scroll down for more updates Donuts and Wings and an IPO 5:24 pm It’s Friday, so treat yourself! Inspire Brands, the private empire behind Dunkin’, Arby’s, Buffalo Wild Wings, Sonic Drive-In, Baskin Robbins, and Jimmy John’s, just confidentially filed for an IPO. Backer Roark Capital wants a $20 billion valuation, which
Today’s Change (7.41%) $4.21 Current Price $61.06 Key Data Points Market Cap $19B Day’s Range $57.91 – $65.58 52wk Range $6.77 – $76.87 Volume 4.4M Avg Vol 35M Gross Margin 26.67% Iren (IREN +7.41%), which develops and operates renewable-powered data centers for Bitcoin (BTC +0.47%) mining and AI cloud services, closed Friday at $61.2, up
While they both have strong long-term track records, the Schwab U.S. Dividend Equity ETF (SCHD +0.25%) and the Vanguard Total Stock Market ETF (VTI +0.76%) construct their portfolios very differently. This Vanguard exchange-traded fund (ETF) essentially invests in the entire investable U.S. equity market. This Schwab ETF targets dividend-paying stocks with healthy balance sheets, long
Image source: The Motley Fool Warren Buffett has been worried about the stock market for some time. Indeed, the legendary conglomerate he and Charlie Munger built, Berkshire Hathaway, has been a net seller of stocks for 14 consecutive quarters. As a result, Berkshire’s now sitting on nearly $400bn in cash! Last weekend, the ‘Oracle of
Michael Burry attends “The Big Short” New York screening Ziegfeld Theater on Nov. 23, 2015 in New York City. Astrid Stawiarz | Getty Images Michael Burry of “Big Short” fame is warning that the stock market’s fixation on artificial intelligence is beginning to resemble the final stages of the dot-com bubble. “Absolutely non-stop AI. Nobody
Traders work on the floor of the New York Stock Exchange during morning trading on May 4, 2026 in New York City. Michael M. Santiago | Getty Images The S&P 500 brushed off Thursday headlines about the U.S. and Iran trading blows in the Strait of Hormuz and continued marching higher in Friday trading, crossing
US jobs data will test whether the AI buildout boom can overpower economic headwinds after the US-Iran war. Nonfarm payrolls are slated for a 62k rise in April while the jobless rate holds steady at 4.3% Leading ISM PMI data warns employment is shrinking, falling jobless claims are misleading The stock market may swoon on
